Cell plasticity represents the ability of cells to be reprogrammed and to change their fate and
identity, enabling homeostasis restoration and tissue regeneration following damage. Cell …

Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Even among genetically identical cancer cells, resistance to therapy frequently emerges
from a small subset of those cells,,,,,–. Molecular differences in rare individual cells in the …

The concept of an epigenetic landscape describing potential cellular fates arising from
pluripotent cells, first advanced by Conrad Waddington, has evolved in light of experiments …

Non-genetic mechanisms have recently emerged as important drivers of cancer therapy
failure, where some cancer cells can enter a reversible drug-tolerant persister state in …

Cellular heterogeneity and an immunosuppressive tumour microenvironment are
independent yet synergistic drivers of tumour progression and underlie therapeutic …

We conducted the Reproducibility Project: Cancer Biology to investigate the replicability of
preclinical research in cancer biology. The initial aim of the project was to repeat 193 …

Platinum (Pt) compounds entered the clinic as anticancer agents when cisplatin was
approved in 1978. More than 40 years later, even in the era of precision medicine and …

Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …